Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SI-B001 plus docetaxel as second-line treatment for advanced or metastatic driver-negative non-small cell lung adenocarcinoma or squamous cell carcinoma after failure of first-line PD-1/PD-L1 inhibitor plus platinum doublet chemotherapy
CTR20231861Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab, docetaxel in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), Pulmonary squamous cell carcinoma, sponsored by Biokin Pharmaceutical. Started Jul 2023; status: active.
02
Drugs
izalontamabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20231861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231861.